Shanghai, China, 07 November 2024 – MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of MicroPort NeuroScientific, recently completed the first post-market implantation of its next-generation Tubridge™ Plus Flow Diverter (Tubridge™ Plus) in China.
The procedure was conducted by the Neurovascular Center team at Changhai Hospital, led by Professors Jianmin Liu, Rui Zhao, and Yina Wu. In their inaugural use of Tubridge™ Plus, they treated a 46-year-old male patient with an ophthalmic segment aneurysm in the left internal carotid artery. Demonstrating exceptional wall apposition and full-body radiopacity, Tubridge™ Plus provided immediate positive results upon deployment.
Following the procedure, Professor Jianmin Liu highlighted that Tubridge™ Plus is, to their knowledge, the world’s first flow diverter featuring “two-dimensional 3D” full-body radiopacity. Each braided wire is fully radiopaque, and two helically wound marker wires enhance contour visibility, enabling precise assessment of deployment and wall apposition. The stent opened smoothly, naturally conforming to the vessel wall without the need for excessive manipulation. Compared to the original Tubridge™ Flow Diverter (Tubridge™), Tubridge™ Plus offers enhanced radial support and is designed for single-person, single-handed deployment through a 27-microcatheter with reduced resistance. The procedure yielded promising results, with follow-up assessments expected to confirm ongoing success.
Since its introduction, Tubridge™ has established numerous milestones, from research to clinical application. Building on this strong foundation, Tubridge™ Plus further addresses key clinical needs through innovative upgrades and received market approval in China in August 2024. To enhance visibility, especially at the skull base, where previous devices encountered radiopacity challenges, Tubridge™ Plus utilizes platinum-core DFT wires in its nickel-titanium composite braiding. Each braided wire ensures excellent radiopacity, and the distinctive helically wound marker wires providing two-dimensional 3D visibility. This optimized structure ensures seamless wall apposition, effectively reducing the risk of thrombosis.
About Intracranial Aneurysms
Intracranial aneurysms, often referred to as “ticking time bombs in the brain”, have been a major focus in interventional neuroradiology since the 2002 International Subarachnoid Aneurysm Trial (ISAT). While interventional methods are a primary treatment for intracranial aneurysms, complex cases involving large or giant aneurysms still face challenges, including procedural complexity, mass effect, and high recurrence rates. Tubridge™ offers a pioneering solution by promoting aneurysm healing and vascular reconstruction through hemodynamic alterations within the parent artery, effectively addressing these “ticking time bombs” and transforming the treatment of intracranial aneurysms.
About MicroPort NeuroScientific
MicroPort NeuroScientific (MicroPort NeuroScientific Corporation; HKEX: 2172), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 120 cerebrovascular stenting procedures every day. In the future, MicroPort NeuroScientific will continue investing more resources in the innovation and development to provide more high-quality and innovative cerebrovascular and neuro-interventional solutions for physicians and patients.
More information is available at: microportneurosci.com